Ovarian Carcinosarcoma Clinical Trials

3 recruiting

Ovarian Carcinosarcoma Trials at a Glance

6 actively recruiting trials for ovarian carcinosarcoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Scottsdale, Rochester, and Jacksonville. Lead sponsors running ovarian carcinosarcoma studies include Mayo Clinic, ARCAGY/ GINECO GROUP, and Australia New Zealand Gynaecological Oncology Group.

Browse ovarian carcinosarcoma trials by phase

Treatments under study

About Ovarian Carcinosarcoma Clinical Trials

Looking for clinical trials for Ovarian Carcinosarcoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ovarian Carcinosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ovarian Carcinosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798
Recruiting
Phase 2

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629
Recruiting
Phase 1

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 2Phase 3

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206
Recruiting
Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Advanced Ovarian CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Primary Peritoneal Carcinoma+15 more
Mayo Clinic78 enrolled3 locationsNCT06639074
Recruiting
Phase 2

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Ovarian CarcinosarcomaUterine Carcinosarcoma
Australia New Zealand Gynaecological Oncology Group30 enrolled6 locationsNCT05619913